+1-888-308-5802     
News Contact Us

iBio unveils the first FastGlycaneering Development Service™

Author : Saipriya Iyer | Published Date : 2019-12-12 

iBio, a renowned New York based biotechnology firm, reportedly launched FastGlycaneering Development Service™, that includes a range of new glycosylation technologies to power high-performance recombinant protein production.

Using iBio’s plant-based manufacturing platform, biosimilar producers and biopharmaceutical innovators would be able to leverage low cost oligomannose modification capabilities, afucosylation controls, and conventional glycosylation techniques to develop novel antibody therapeutics, biosimilars and high-quality biobetters.

Tom Isett, a member of Board of Directors, iBio, reportedly stated that combining the speed of iBio’s FastPharming Manufacturing System™ with the advanced glycan engineering technologies creates a more effective and efficient alternative of producing biopharmaceuticals in cell-based mammalian systems or CHO. Isett further added that Dr. Sylvain Marcel, VP of Protein Expression Sciences is likely to unlock iBio’s N. benthamiana expression system with these innovations.

Robert B. Kay, CEO and Chairman, iBio, reportedly stated that the company has taken another step with proven results in the manufacturing of growth factors, virus-like particles, biologics, fusion proteins and monoclonal antibodies. The company is thrilled to present new services of FastGlycaneering during the Antibody Engineering & Therapeutics meeting held in San Diego, CA, during a talk.

About iBio:

iBio, Inc., is a globally recognized full-service biologics manufacturing firm. iBio’s FastPharming System™ combines automated hydroponics, glycan engineering and vertical farming technologies that are capable of rapidly delivering high-quality vaccines, bioinks, monoclonal antibodies and proteins.

The team of iBio comprises of knowledgeable microbiologists, protein scientists, regulatory and manufacturing experts that use their expertise and value throughout the entire process. The team producing clinical and preclinical material also produces products for market launch, thereby contributing to the scale-up process platform created by iBio technology.

The FastPharming platform produces a variety of products including, antigens for subunit vaccine design, VLP (Virus-like particles), lysosomal enzymes, biobetter and biosimilar antibodies, blood factors and cytokines, maturogens, scaffolds and, materials for 3D biofabrication and bioprinting.

 

Source credit: https://www.ibioinc.com/news/ibio-introduces-fastglycaneering-development-service-to-power-recombinant-protein-production

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

TWU accuses Qantas of inactivity as more worker test COVID-19 positive

Published Date: 2020-04-02         Author: Saipriya Iyer

The union for airline baggage holders, TWU (Transport Workers’ Union), has reportedly accused Qantas Airways, the largest Airline network of Australia, of not ensuring worker safety against COVID-19 after the company’s baggage handlers tested positive for coronavirus. The Union stated... Read More

Houseparty to offer $1M reward to anyone providing proof of sabotage

Published Date: 2020-04-01         Author: Saipriya Iyer

Houseparty, a social networking service, has recently announced a $1 million reward to anyone who can uncover a commercial smear campaign that spread rumors alleging cyber breach of other services. The company has been purchased from its creator by Fortnite developer, Epic Games, in 2019. The sit... Read More

Ever Harmonic to acquire CCO’s Clear Media stake for US$253Mn

Published Date: 2020-03-31         Author: Saipriya Iyer

Clear Channel Outdoor Holdings Inc. (CCO), one of the leading outdoor advertising companies, has reportedly inked an agreement with Ever Harmonic Global Limited, under which it would sell its 50.91% stake in China-based media company, Clear Media Ltd. For the record, Ever Harmonic is fully owned ... Read More

© 2020 Fractovia. All Rights Reserved